TY - JOUR
T1 - Safety profile of COVID-19 vaccines, preventive strategies, and patient management
AU - Prabhu, M. Mukhyaprana
AU - Palaian, Subish
AU - Ansari, Mukhtar
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Introduction: Fast-track approval has led to serious concerns on the perception of COVID-19 vaccines’ safety among the public. Common adverse drug reactions (ADRs) of COVID-19 vaccines are minor localized reactions, while systemic ADRs have been reported rarely. The serious ADRs include anaphylaxis, vaccine-induced immune thrombotic thrombocytopenia syndrome (VITTS), and reactions related to the pharmaceutical excipients present in the vaccine. A comprehensive review on the safety of COVID-19 vaccines would help in early identification and better management of ADRs. This literature review was conducted using PubMed, Google Scholar, COVID-19 Vaccine package inserts, and UpToDate. Areas covered: This article provides various aspects of COVID-19 vaccine safety and offers strategies to prevent and clinically manage suspected ADRs related to COVID-19 vaccines. Expert opinion: A careful consideration of contraindications and patient education on early identification of serious ADRs are the cornerstones in tackling safety concerns associated with COVID-19 vaccines. Most of the mild ADR cases are manageable with over-the-counter medications, while the serious ones may require physician oversight and hospitalization. It is also mandatory to report all ADRs to the local pharmacovigilance centers, with a higher priority given to the moe significant ones, in order to improve vaccine safety data.
AB - Introduction: Fast-track approval has led to serious concerns on the perception of COVID-19 vaccines’ safety among the public. Common adverse drug reactions (ADRs) of COVID-19 vaccines are minor localized reactions, while systemic ADRs have been reported rarely. The serious ADRs include anaphylaxis, vaccine-induced immune thrombotic thrombocytopenia syndrome (VITTS), and reactions related to the pharmaceutical excipients present in the vaccine. A comprehensive review on the safety of COVID-19 vaccines would help in early identification and better management of ADRs. This literature review was conducted using PubMed, Google Scholar, COVID-19 Vaccine package inserts, and UpToDate. Areas covered: This article provides various aspects of COVID-19 vaccine safety and offers strategies to prevent and clinically manage suspected ADRs related to COVID-19 vaccines. Expert opinion: A careful consideration of contraindications and patient education on early identification of serious ADRs are the cornerstones in tackling safety concerns associated with COVID-19 vaccines. Most of the mild ADR cases are manageable with over-the-counter medications, while the serious ones may require physician oversight and hospitalization. It is also mandatory to report all ADRs to the local pharmacovigilance centers, with a higher priority given to the moe significant ones, in order to improve vaccine safety data.
UR - http://www.scopus.com/inward/record.url?scp=85131071106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131071106&partnerID=8YFLogxK
U2 - 10.1080/14760584.2022.2078311
DO - 10.1080/14760584.2022.2078311
M3 - Review article
C2 - 35559718
AN - SCOPUS:85131071106
SN - 1476-0584
VL - 21
SP - 1087
EP - 1095
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 8
ER -